Liraglutide – Next-Generation Antidiabetic Medication
Key Data:
Drug (Brand/Generic)
Liraglutide
Company/Licensee
Novo Nordisk
Therapy Class
GLP-1 analogue
Product Description
Long-acting human analogue of naturally occurring hormone, GLP-1
Current Indication
Type 2 diabetic patients poorly controlled with diet plus metformin and/or sulfonylureas
Market Sector
Diabetes
Development Status
Pre-registration US and Europe
